Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGb 761 in MCI with CVD
NCT04525144Phase 2Recruiting
- Sponsor
- National Neuroscience Institute
- Start
- Oct 2020
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by National Neuroscience Institute. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive 13 at 52 weeks and Clinical Dementia Rating Sum of Boxes at 52 weeks. Started Oct 2020; status: recruiting.
Beyond the preview
Go deeper on NCT04525144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525144.